Amylyx Pharmaceuticals, Inc. (AMLX)
33.75
-0.99
(-2.85%)
USD |
NASDAQ |
Aug 31, 16:00
33.50
-0.25
(-0.74%)
Pre-Market: 09:08
Amylyx Pharmaceuticals Cash from Investing (Quarterly) : -149.80M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -149.80M |
| March 31, 2026 | 36.26M |
| December 31, 2025 | 29.47M |
| September 30, 2025 | 5.236M |
| June 30, 2025 | 22.99M |
| March 31, 2025 | -43.66M |
| December 31, 2024 | 64.98M |
| September 30, 2024 | 38.82M |
| June 30, 2024 | -28.96M |
| March 31, 2024 | 0.819M |
| December 31, 2023 | 20.92M |
| September 30, 2023 | -108.09M |
| Date | Value |
|---|---|
| June 30, 2023 | 123.22M |
| March 31, 2023 | 55.99M |
| December 31, 2022 | -228.18M |
| September 30, 2022 | 84.04M |
| June 30, 2022 | 4.462M |
| March 31, 2022 | -99.31M |
| December 31, 2021 | 2.814M |
| September 30, 2021 | -49.21M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -0.014M |
| December 31, 2020 | -0.151M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | 2.106B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| EyePoint, Inc. | 75.10M |
| Bristol Myers Squibb Co. | -1.614B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -31.42M |
| Cash from Financing (Quarterly) | 1.479M |
| Free Cash Flow | -130.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2829 |
| Free Cash Flow to Equity (Quarterly) | -31.08M |
| Free Cash Flow to Firm (Quarterly) | -31.45M |
| Free Cash Flow Yield | -3.65% |